Endocrine Testing Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently released a comprehensive report on the global Endocrine Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.
Key Insights:
Endocrine Testing Market Size (2025E): US$ 13.4 Bn
Projected Market Value (2032F): US$ 23.2 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 8.2%
Endocrine Testing Market - Report Scope:
The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.
Market Growth Drivers:
The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies—such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods—are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.
Market Restraints:
Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.
Market Opportunities:
The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions—such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays—that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.
Key Questions Answered in the Report:
What are the primary factors driving the global endocrine testing market's growth?
Which test types and technologies are gaining the most traction among healthcare providers?
How are innovations in diagnostic tools impacting endocrine disease management?
Who are the major players in the endocrine testing market, and what strategies are they employing?
What are the regional trends and long-term projections for the endocrine testing market?
Competitive Intelligence and Business Strategy:
Leading players in the global endocrine testing market—including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche—are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.
Companies Covered in This Report:
Abbott Laboratories, Inc.
AB Sciex Pte. Ltd.
Agilent Technologies, Inc.
bioMérieux SA
Bio-Rad Laboratories Inc.
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd.
Laboratory Corporation of America Holdings (LabCorp)
Quest Diagnostics, Inc.
Thermo Fisher Scientific, Inc.
Market Segmentation:
By Test:
Testosterone Test
Estradiol Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Luteinizing Hormone (LH) Test
Progesterone Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Insulin Test
Others
By Technology:
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Clinical Chemistry Analyzers
Others
By Disease Indication:
Diabetes
Hyperthyroidism
Menopause
Osteoporosis
Cancer
Others
By End Use:
Hospitals
Diagnostic Laboratories
Ambulatory Care Centers
Home-based Tests
Specialty Centers
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
Endocrine Testing Market Size (2025E): US$ 13.4 Bn
Projected Market Value (2032F): US$ 23.2 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 8.2%
Endocrine Testing Market - Report Scope:
The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.
Market Growth Drivers:
The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies—such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods—are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.
Market Restraints:
Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.
Market Opportunities:
The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions—such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays—that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.
Key Questions Answered in the Report:
What are the primary factors driving the global endocrine testing market's growth?
Which test types and technologies are gaining the most traction among healthcare providers?
How are innovations in diagnostic tools impacting endocrine disease management?
Who are the major players in the endocrine testing market, and what strategies are they employing?
What are the regional trends and long-term projections for the endocrine testing market?
Competitive Intelligence and Business Strategy:
Leading players in the global endocrine testing market—including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche—are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.
Companies Covered in This Report:
Abbott Laboratories, Inc.
AB Sciex Pte. Ltd.
Agilent Technologies, Inc.
bioMérieux SA
Bio-Rad Laboratories Inc.
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd.
Laboratory Corporation of America Holdings (LabCorp)
Quest Diagnostics, Inc.
Thermo Fisher Scientific, Inc.
Market Segmentation:
By Test:
Testosterone Test
Estradiol Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Luteinizing Hormone (LH) Test
Progesterone Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Insulin Test
Others
By Technology:
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal Antibody Technologies
Clinical Chemistry Analyzers
Others
By Disease Indication:
Diabetes
Hyperthyroidism
Menopause
Osteoporosis
Cancer
Others
By End Use:
Hospitals
Diagnostic Laboratories
Ambulatory Care Centers
Home-based Tests
Specialty Centers
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- 1. Executive Summary
- 1.1. Global Endocrine Testing Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. COVID-19 Impact Analysis
- 2.4. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Value Chain Analysis
- 3.2. Test Adoption / Usage Analysis
- 3.3. Government Initiatives & Funding in Endocrine Testing
- 3.4. Key Market Players
- 3.5. Regulatory Landscape
- 3.6. PESTLE Analysis
- 3.7. Porter’s Five Force Analysis
- 3.8. Consumer Behavior Analysis
- 4. Global Endocrine Testing Market Outlook
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Endocrine Testing Market Outlook: Test
- 4.3.1. Historical Market Size (US$ Bn) Analysis, By Test, 2019-2024
- 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 4.3.2.1. Testosterone Test
- 4.3.2.2. Estradiol Test
- 4.3.2.3. Thyroid Stimulating Hormone (TSH) Test
- 4.3.2.4. Prolactin Test
- 4.3.2.5. Luteinizing Hormone (LH) Test
- 4.3.2.6. Progesterone Test
- 4.3.2.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 4.3.2.8. Insulin Test
- 4.3.2.9. Others
- 4.3.3. Market Attractiveness Analysis: Test
- 4.4. Global Endocrine Testing Market Outlook: Technology
- 4.4.1. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
- 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 4.4.2.1. Tandem Mass Spectrometry
- 4.4.2.2. Monoclonal & Polyclonal Antibody Technologies
- 4.4.2.3. Clinical Chemistry
- 4.4.2.4. Immunoassay
- 4.4.2.5. Others
- 4.4.3. Market Attractiveness Analysis: Technology
- 4.5. Global Endocrine Testing Market Outlook: Disease Indication
- 4.5.1. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2024
- 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 4.5.2.1. Diabetes
- 4.5.2.2. Hyperthyroidism
- 4.5.2.3. Menopause
- 4.5.2.4. Osteoporosis
- 4.5.2.5. Cancer
- 4.5.2.6. Others
- 4.5.3. Market Attractiveness Analysis: Disease Indication
- 4.6. Global Endocrine Testing Market Outlook: End-use
- 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
- 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 4.6.2.1. Hospitals
- 4.6.2.2. Diagnotics Laboratories
- 4.6.2.3. Ambulatory Care Centers
- 4.6.2.4. Home-based Tests
- 4.6.2.5. Speciality Centers
- 4.6.2.6. Others
- 4.6.3. Market Attractiveness Analysis: End-use
- 5. Global Endocrine Testing Market Outlook Region
- 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.2.1. North America
- 5.2.2. Latin America
- 5.2.3. Europe
- 5.2.4. East Asia
- 5.2.5. South Asia and Oceania
- 5.2.6. Middle East & Africa
- 5.3. Market Attractiveness Analysis: Region
- 6. North America Endocrine Testing Market Outlook
- 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.1.1. By Country
- 6.1.2. By Test
- 6.1.3. By Technology
- 6.1.4. By Disease Indication
- 6.1.5. By End-Use
- 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.2.1. U.S.
- 6.2.2. Canada
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 6.3.1. Testosterone Test
- 6.3.2. Estradiol Test
- 6.3.3. Thyroid Stimulating Hormone (TSH) Test
- 6.3.4. Prolactin Test
- 6.3.5. Luteinizing Hormone (LH) Test
- 6.3.6. Progesterone Test
- 6.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 6.3.8. Insulin Test
- 6.3.9. Others
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 6.4.1. Tandem Mass Spectrometry
- 6.4.2. Monoclonal & Polyclonal Antibody Technologies
- 6.4.3. Clinical Chemistry
- 6.4.4. Immunoassay
- 6.4.5. Others
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 6.5.1. Diabetes
- 6.5.2. Hyperthyroidism
- 6.5.3. Menopause
- 6.5.4. Osteoporosis
- 6.5.5. Cancer
- 6.5.6. Others
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 6.6.1. Hospitals
- 6.6.2. Diagnotics Laboratories
- 6.6.3. Ambulatory Care Centers
- 6.6.4. Home-based Tests
- 6.6.5. Speciality Centers
- 6.6.6. Others
- 6.7. Market Attractiveness Analysis
- 7. Europe Endocrine Testing Market Outlook
- 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.1.1. By Country
- 7.1.2. By Test
- 7.1.3. By Technology
- 7.1.4. By Disease Indication
- 7.1.5. By End-use
- 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. U.K.
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 7.3.1. Testosterone Test
- 7.3.2. Estradiol Test
- 7.3.3. Thyroid Stimulating Hormone (TSH) Test
- 7.3.4. Prolactin Test
- 7.3.5. Luteinizing Hormone (LH) Test
- 7.3.6. Progesterone Test
- 7.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 7.3.8. Insulin Test
- 7.3.9. Others
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 7.4.1. Tandem Mass Spectrometry
- 7.4.2. Monoclonal & Polyclonal Antibody Technologies
- 7.4.3. Clinical Chemistry
- 7.4.4. Immunoassay
- 7.4.5. Others
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 7.5.1. Diabetes
- 7.5.2. Hyperthyroidism
- 7.5.3. Menopause
- 7.5.4. Osteoporosis
- 7.5.5. Cancer
- 7.5.6. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 7.6.1. Hospitals
- 7.6.2. Diagnotics Laboratories
- 7.6.3. Ambulatory Care Centers
- 7.6.4. Home-based Tests
- 7.6.5. Speciality Centers
- 7.6.6. Others
- 7.7. Market Attractiveness Analysis
- 8. East Asia Endocrine Testing Market Outlook
- 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.1.1. By Country
- 8.1.2. By Test
- 8.1.3. By Disease Indication
- 8.1.4. By End-Use
- 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.2.1. China
- 8.2.2. Japan
- 8.2.3. South Korea
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 8.3.1. Testosterone Test
- 8.3.2. Estradiol Test
- 8.3.3. Thyroid Stimulating Hormone (TSH) Test
- 8.3.4. Prolactin Test
- 8.3.5. Luteinizing Hormone (LH) Test
- 8.3.6. Progesterone Test
- 8.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 8.3.8. Insulin Test
- 8.3.9. Others
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 8.4.1. Tandem Mass Spectrometry
- 8.4.2. Monoclonal & Polyclonal Antibody Technologies
- 8.4.3. Clinical Chemistry
- 8.4.4. Immunoassay
- 8.4.5. Others
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 8.5.1. Diabetes
- 8.5.2. Hyperthyroidism
- 8.5.3. Menopause
- 8.5.4. Osteoporosis
- 8.5.5. Cancer
- 8.5.6. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 8.6.1. Hospitals
- 8.6.2. Diagnotics Laboratories
- 8.6.3. Ambulatory Care Centers
- 8.6.4. Home-based Tests
- 8.6.5. Speciality Centers
- 8.6.6. Others
- 8.7. Market Attractiveness Analysis
- 9. South Asia & Oceania Endocrine Testing Market Outlook
- 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.1.1. By Country
- 9.1.2. By Test
- 9.1.3. By Technology
- 9.1.4. By Disease Indication
- 9.1.5. By End-Use
- 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.2.1. India
- 9.2.2. Indonesia
- 9.2.3. Thailand
- 9.2.4. Singapore
- 9.2.5. ANZ
- 9.2.6. Rest of South Asia & Oceania
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 9.3.1. Testosterone Test
- 9.3.2. Estradiol Test
- 9.3.3. Thyroid Stimulating Hormone (TSH) Test
- 9.3.4. Prolactin Test
- 9.3.5. Luteinizing Hormone (LH) Test
- 9.3.6. Progesterone Test
- 9.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 9.3.8. Insulin Test
- 9.3.9. Others
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 9.4.1. Tandem Mass Spectrometry
- 9.4.2. Monoclonal & Polyclonal Antibody Technologies
- 9.4.3. Clinical Chemistry
- 9.4.4. Immunoassay
- 9.4.5. Others
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 9.5.1. Diabetes
- 9.5.2. Hyperthyroidism
- 9.5.3. Menopause
- 9.5.4. Osteoporosis
- 9.5.5. Cancer
- 9.5.6. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 9.6.1. Hospitals
- 9.6.2. Diagnotics Laboratories
- 9.6.3. Ambulatory Care Centers
- 9.6.4. Home-based Tests
- 9.6.5. Speciality Centers
- 9.6.6. Others
- 9.7. Market Attractiveness Analysis
- 10. Latin America Endocrine Testing Market Outlook
- 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.1.1. By Country
- 10.1.2. By Test
- 10.1.3. BY Technology
- 10.1.4. By Disease Indication
- 10.1.5. By End-Use
- 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.2.1. Brazil
- 10.2.2. Mexico
- 10.2.3. Rest of Latin America
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 10.3.1. Testosterone Test
- 10.3.2. Estradiol Test
- 10.3.3. Thyroid Stimulating Hormone (TSH) Test
- 10.3.4. Prolactin Test
- 10.3.5. Luteinizing Hormone (LH) Test
- 10.3.6. Progesterone Test
- 10.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 10.3.8. Insulin Test
- 10.3.9. Others
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 10.4.1. Tandem Mass Spectrometry
- 10.4.2. Monoclonal & Polyclonal Antibody Technologies
- 10.4.3. Clinical Chemistry
- 10.4.4. Immunoassay
- 10.4.5. Others
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 10.5.1. Diabetes
- 10.5.2. Hyperthyroidism
- 10.5.3. Menopause
- 10.5.4. Osteoporosis
- 10.5.5. Cancer
- 10.5.6. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 10.6.1. Hospitals
- 10.6.2. Diagnotics Laboratories
- 10.6.3. Ambulatory Care Centers
- 10.6.4. Home-based Tests
- 10.6.5. Speciality Centers
- 10.6.6. Others
- 10.7. Market Attractiveness Analysis
- 11. Middle East & Africa Endocrine Testing Market Outlook
- 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.1.1. By Country
- 11.1.2. By Test
- 11.1.3. By Technology
- 11.1.4. By Disease Indication
- 11.1.5. By End-Use
- 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.2.1. GCC Countries
- 11.2.2. Egypt
- 11.2.3. South Africa
- 11.2.4. Northern Africa
- 11.2.5. Rest of Middle East & Africa
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
- 11.3.1. Testosterone Test
- 11.3.2. Estradiol Test
- 11.3.3. Thyroid Stimulating Hormone (TSH) Test
- 11.3.4. Prolactin Test
- 11.3.5. Luteinizing Hormone (LH) Test
- 11.3.6. Progesterone Test
- 11.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
- 11.3.8. Insulin Test
- 11.3.9. Others
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 11.4.1. Tandem Mass Spectrometry
- 11.4.2. Monoclonal & Polyclonal Antibody Technologies
- 11.4.3. Clinical Chemistry
- 11.4.4. Immunoassay
- 11.4.5. Others
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 11.5.1. Diabetes
- 11.5.2. Hyperthyroidism
- 11.5.3. Menopause
- 11.5.4. Osteoporosis
- 11.5.5. Cancer
- 11.5.6. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
- 11.6.1. Hospitals
- 11.6.2. Diagnotics Laboratories
- 11.6.3. Ambulatory Care Centers
- 11.6.4. Home-based Tests
- 11.6.5. Speciality Centers
- 11.6.6. Others
- 11.7. Market Attractiveness Analysis
- 12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Abbott Laboratories, Inc.
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Sources
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. AB Sciex Pte. Ltd.
- 12.3.3. Agilent Technologies, Inc.
- 12.3.4. bioMerieux SA
- 12.3.5. Bio-Rad Laboratories Inc.
- 12.3.6. DiaSorin S.p.A.
- 12.3.7. F. Hoffmann-La Roche Ltd.
- 12.3.8. Laboratory Corporation of America Holdings (LabCorp)
- 12.3.9. Quest Diagnostics, Inc.
- 12.3.10. Thermo Fisher Scientific, Inc.
- 12.3.11. MP Biomedicals
- 12.3.12. Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
- 12.3.13. Siemens Healthineers AG
- 12.3.14. Sysmex Corporation
- 12.3.15. Others
- 13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
